1Koomanachai P, Crandon JL, Nicolau DP, et al. Compara- tive pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program[J]. Int J Antimicrob A- gents, 2009,33 (4) : 348-353.
2Frei CR, Wiederhold NP, Burgess DS. Antimicrobial break- points for gram-negative aerobic bacteria based on pharma- cokinetic pharmacodynamic models with monte carlo simula- tion[J]. J Antimicrob Chemother, 2008, 61(3 ) : 621-628.
3Crandon JL, Joseph LK, Ronald N, et al. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance[J]. Ann Pharmacother, 2009,43 ( 2 ) : 220-227.
4Jason A, Roberts, Carl M,et al. Monte carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clin- ical practice for critically ill patients[J]. J Antimicrob Che- mother, 2011, 66(2) : 227-231.
5Travis WC, Steven EP, Sara DB, et al. Can pharmacokinetic and pharmacodynamic principles be applied to the treatment of multidrug-resistant acinetobacter[J]. Ann Pharmacother, 2011,45 (2) : 229-240.
6Kathryn J, Eagye M, Joseph L,et al. In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coliand Pseudomonas aeruginosa at forty US hospitals[J]. Clin Ther, 2009,31 ( 11 ) : 2678-2688.
7Keel RA, Zhanel GS, Zelenitsky DP, et al. Pharmacody- namic profiling of antimicrobials against gram-negative res- piratory isolates from canadian hospitals[J]. J Infect Dis Med Microbiol, 2011,22(4 ) : 132-136.
8Mouton JW, Dudley MN, Cars O,et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for antiinfective drugs: an update[J]. J Antimicrob Chemother, 2009,55 (5) : 601-607.
9Lois SL, Martina KS, Anne N, et al. Comparison of 30-min and 3-h infusion regimens for imipenem/eilastatin and for meropenem evaluated by monte carlo simulation[J]. Diagn Mierobiol Infect Dis, 2010,68 ( 3 ) : 251-258.
10Canut AA,Isla C, Betriu AR,et al. Pharmacokinetic-phar- macodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomyein for the treatment of MRSA in- fections in four western european countries[J]. Eur J Clin Mi- crobiol Infect Dis, 2012,14( 11 ) : 2227-2235.
